SCHEMBL30544024

SCHEMBL30544024

CS(=O)(=O)Nc1cccc(NC(=O)c2cc(C(=O)NCc3n[nH]c4ccccc34)cs2)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A1 P68400 6/20 0.47
▸ FLT3 P36888 2/20 0.41
▸ MAP4K1 Q92918 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ CDK5 Q00535 1/20 0.40
▸ CDK5R1 Q15078 1/20 0.40
▸ DHX9 Q08211 1/20 0.40
▸ CSNK1D P48730 1/20 0.40
▸ BRD4 O60885 1/20 0.39
▸ ROCK2 O75116 3/20 0.39
▸ NFATC1 O95644 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ USP7 Q93009 1/20 0.39
▸ USP47 Q96K76 1/20 0.39
▸ ROCK1 Q13464 2/20 0.38
▸ CCNE1 P24864 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ CDK3 Q00526 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25432990 1.00 CSNK2A1 (0.47) CSNK2A1FLT3MAP4K1MAPK1CDK5
SCHEMBL25370694 0.81 SMN1; SMN2 (0.49) MEN1KMT2AROCK1
SCHEMBL30544011 0.81 SMN1; SMN2 (0.49) MEN1KMT2AROCK1
SCHEMBL25432009 0.79 MEN1 (0.52) MEN1KMT2A
SCHEMBL25368280 0.78 DHX9 (0.53) MAPK1DHX9MEN1KMT2A
SCHEMBL30543946 0.78 DHX9 (0.53) MAPK1DHX9MEN1KMT2A
SCHEMBL25433357 0.78 NFATC1 (0.54) DHX9ROCK2NFATC1MEN1KMT2A
SCHEMBL30543915 0.77 ALDH1A1 (0.46) DHX9ROCK2USP7USP47ROCK1
SCHEMBL25367979 0.77 ALDH1A1 (0.46) DHX9ROCK2USP7USP47ROCK1
SCHEMBL25368472 0.76 LMNA (0.48) DHX9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
EP-4479380-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 — — EP disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B CSNK2A1 3645/4885FLT3 4061/4885MAP4K1 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback